NVO

Novo Nordisk ADR

Jan 30 • 04:00PM ET

59.43

+0.10 0.17 %

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN PFE SNY BMY GSK

| Held by: PVAL PPH AVDE PINK FTHI PID WCMI RVER OZEM AQEC

Index	-	P/E	17.31	EPS (ttm)	3.43	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	-4.55%
Market Cap	200.20B	Forward P/E	17.34	EPS next Y	3.43	Insider Trans	-	Shs Float	3.37B	Perf Month	16.03%
Enterprise Value	211.00B	PEG	3.55	EPS next Q	0.92	Inst Own	9.03%	Short Float	0.84%	Perf Quarter	15.69%
Income	15.29B	P/S	4.29	EPS this Y	16.88%	Inst Trans	-1.57%	Short Ratio	1.36	Perf Half Y	26.26%
Sales	46.69B	P/B	9.87	EPS next Y	-7.23%	ROA	21.83%	Short Interest	28.16M	Perf YTD	16.80%
Book/sh	6.02	P/C	39.03	EPS next 5Y	4.89%	ROE	68.30%	52W High	93.80 -36.64%	Perf Year	-29.28%
Cash/sh	1.52	P/FCF	20.01	EPS past 3/5Y	25.78% 21.74%	ROIC	37.50%	52W Low	43.08 37.95%	Perf 3Y	-14.42%
Dividend Est.	1.81 (3.04%)	EV/EBITDA	9.16	Sales past 3/5Y	23.46% 18.15%	Gross Margin	81.93%	Volatility	2.10% 2.76%	Perf 5Y	62.42%
Dividend TTM	1.73 (2.91%)	EV/Sales	4.52	EPS Y/Y TTM	11.24%	Oper. Margin	42.41%	ATR (14)	2.07	Perf 10Y	117.14%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	0.57	Sales Y/Y TTM	18.71%	Profit Margin	32.76%	RSI (14)	55.16	Recom	2.29
Dividend Gr. 3/5Y	28.20% 21.81%	Current Ratio	0.78	EPS Q/Q	-21.84%	SMA20	0.32%	Beta	0.67	Target Price	62.16
Payout	35.93%	Debt/Eq	0.60	Sales Q/Q	11.80%	SMA50	12.15%	Rel Volume	0.58	Prev Close	59.33
Employees	76302	LT Debt/Eq	0.52	Earnings	Feb 04 BMO	SMA200	0.96%	Avg Volume	20.73M	Price	59.43
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.41% -3.47%	Trades		Volume	12,085,775	Change	0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral
Jul-31-25	Downgrade	HSBC Securities	Buy → Hold	$57
Jul-30-25	Downgrade	Barclays	Overweight → Equal Weight
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120

Show Previous Ratings

Today 12:35PM	BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures (Insider Monkey)
12:30PM	Starbucks CEO Brian Niccol says rise of GLP-1s is behind company's protein push (Yahoo Finance)
07:05AM	Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? (Motley Fool)
12:24AM	Eli Lilly CEO Says Medicare Coverage Of Obesity Drugs Could Be Game-Changer For Its Weight-Loss Pill (Benzinga)
Jan-30-26 06:44PM	Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? (Motley Fool)
04:57PM	Loading…
04:57PM	Jobs Report, More Tech Earnings: What to Watch Next Week (The Wall Street Journal)
01:59PM	Novo Jumps Ahead as Wegovy Pill Takes Off (GuruFocus.com)
12:57PM	Novo Nordisk Outspends Eli Lilly On Wegovy, Ozempic Ads After Supply Crunch Eases (Benzinga)
11:11AM	lkj lkj lkj lkj lkj lkj (Test Provider for Finance)
10:57AM	Novo Nordisk Shares Jump 14% as Wegovy Pill Launch Lifts Sentiment (GuruFocus.com)
10:08AM	Novo Nordisk Sued Over Alleged Scheme To Delay Generic Victoza In Favor Of Ozempic (Benzinga)
10:06AM	Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? (Zacks)
09:55AM	Novo's Wegovy pill surpasses 26,000 prescriptions in second full week (Reuters Videos)
08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
07:58AM	Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? (Zacks)
03:00AM	Loading…
03:00AM	How Big Pharma is navigating a $300 billion patent cliff (Pharma Voice)
02:53AM	Novo Obesity Pill Spurs Rally After Stocks Worst Ever Year (Bloomberg)
02:51AM	AstraZeneca Strikes Multibillion-Dollar Obesity Deal With Chinas CSPC (The Wall Street Journal)
Jan-29-26 04:22PM	How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity (Investor's Business Daily)
12:36PM	Novo Nordisk Faces Class Action Over Victoza Generic Delay (GuruFocus.com)
09:48AM	RHHBY's 2025 Results Hit by Currency Headwinds, Sales Up 7% at CER (Zacks)
06:58AM	Novo Nordisk Doubles U.S. Ad Spend on Wegovy, Ozempic (GuruFocus.com)
Jan-28-26 04:20PM	2 Beaten-Down Growth Stocks Ready to Bounce Back (Motley Fool)
03:01PM	Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25% (GuruFocus.com)
12:20PM	Layoffs are piling up, heightening worker anxiety. Here are some of the biggest job cuts recently (Associated Press Finance)
09:09AM	Roche Reports Upbeat Efficacy Data From Phase II Obesity Study (Zacks)
06:31AM	India Obesity Drug Fight Is About to Intensify (GuruFocus.com)
06:06AM	Exclusive-Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows (Reuters)
01:50AM	1 Biotech Stock Set to Rebound in 2026 (Motley Fool)
Jan-27-26 05:45PM	Novo Nordisk (NVO) Stock Declines While Market Improves: Some Information for Investors (Zacks)
02:35PM	Loading…
02:35PM	Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss (GuruFocus.com)
01:00PM	1 Pharmaceutical Stock Set to Rebound in 2026 (Motley Fool)
12:32PM	Another Government Shutdown Looms: These 10 Stocks Suffered Last Time (Benzinga)
11:16AM	Citi initiates coverage of European pharma stocks; AstraZeneca best in class (Investing.com)
10:37AM	2 Pharmaceutical Stocks Set to Rebound in 2026 (Motley Fool)
09:41AM	Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet? (Zacks)
09:27AM	Where Will Eli Lilly Be in 10 Years? (Motley Fool)
06:31AM	Roche, trailing in obesity, showcases new data for GLP-1 shot (BioPharma Dive)
06:21AM	Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight (Benzinga)
04:10AM	Roche Obesity Shot Helps Patients Lose Weight in Midstage Trial (The Wall Street Journal)
Jan-26-26 09:20AM	Prediction: This Healthcare Stock Could Soar by 40% in 2026 (Motley Fool)
09:15AM	How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results? (Zacks)
Jan-24-26 08:35PM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
03:25PM	Should You Dump Eli Lilly's Shares After This Setback? (Motley Fool)
Jan-23-26 04:04PM	Oral Wegovy Is Off To An Astronomical Launch. Will It Save Novo Nordisk Stock? (Investor's Business Daily)
12:58PM	Novo Nordisk Wegovy Pill Sees Strong Launch (GuruFocus.com)
12:06PM	Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues (Investor's Business Daily)
10:36AM	VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion (24/7 Wall St.)
09:18AM	Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It (Benzinga)
09:12AM	Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record (Benzinga)
09:00AM	Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now? (Zacks)
05:30AM	Premarket movers: Intel tumbles, Capital One slips, Spotify gains (MarketWatch)
05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
04:28AM	It's a hit: Wegovy weight-loss drug pill prescriptions surge (MarketWatch)
Jan-22-26 09:10AM	Jim Cramer on Novo Nordisk: "I Think They're Making a Turn Here" (Insider Monkey)
Jan-21-26 05:45PM	Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
04:39PM	Why Eli Lilly Is The IBD Stock Of The Day Again As Its Novo Nordisk Rivalry Deepens (Investor's Business Daily)
03:32PM	Markets Rally As Trump Drops Greenland's Tariff Threat: These 10 Stocks Are Soaring (Benzinga)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
10:00AM	The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1? (Barchart)
06:34AM	Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies (Pharmaceutical Business Review)
Jan-20-26 03:05PM	Is Oral Wegovy a Game Changer for Novo Nordisk? (Motley Fool)
01:21PM	Novo Nordisk Expands Diabetes Partnership With Aspect Biosystems (GuruFocus.com)
08:08AM	Which Pharma Stock Stands Taller Right Now: LLY or PFE? (Zacks)
Jan-19-26 03:23PM	Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (MarketBeat)
01:05PM	Europe's Growth At Risk If Trump Acts On Greenland, Goldman Sachs Warns (Benzinga)
10:24AM	Compounder sues Lilly and Novo for suppressing GLP-1RA competition (Pharmaceutical Technology)
09:59AM	Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already? (Zacks)
08:17AM	European Stock Markets Tumble on Trumps Tariff Threats, But Analysts Caution Against Panic (The Wall Street Journal)
08:01AM	Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus (Zacks)
Jan-16-26 05:18PM	Stocks to Watch Friday Recap: J.B. Hunt, Salesforce, PNC (The Wall Street Journal) +9.12%
05:07PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:30PM	Stock Market Today: S&P 500, Dow Slide As Netflix, GE Aerospace Earnings Loom (Live Coverage) (Investor's Business Daily)
04:18PM	Todays Stock Movers: GE Vernova, Constellation Energy, Micron, AST SpaceMobile, Novo Nordisk, and More (Barrons.com)
04:12PM	Novo's Wegovy Pill Is Following In Zepbound's Footsteps And It's Only Been One Week (Investor's Business Daily)
02:54PM	These Stocks Are Todays Movers: GE Vernova, Constellation Energy, Micron, AST SpaceMobile, Novo Nordisk, and More (Barrons.com)
01:43PM	Stocks to Watch Friday: J.B. Hunt, PNC, Verizon (The Wall Street Journal)
01:27PM	Stock Market Today: Dow, S&P Waffle As Battered Obesity Drug Giant Soars (Live Coverage) (Investor's Business Daily)
01:21PM	Novo Nordisk Jumps on Higher Wegovy Dose (GuruFocus.com)
01:06PM	Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? (Motley Fool)
12:59PM	Novo Nordisk Stock Jumps. The Wegovy Pill Is Back in Focus (GuruFocus.com)
12:46PM	Novo Nordisk (NVO) is "in a Battle," Says Jim Cramer (Insider Monkey)
12:07PM	Novo Nordisk's Newly Approved Weight Loss Pill Shows Record Prescription Data (Benzinga)
11:19AM	Novo Nordisk's Wegovy Weight Loss Pill Has a Strong Launch-and Other Reasons the Stock Is Rising (Barrons.com)
10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks)
10:22AM	Novo shares jump on 'encouraging' Wegovy pill scripts data, analysts say (Reuters Videos)
09:33AM	Why A 'Solid' First Week For Oral Wegovy Bodes Well For Novo And Lilly (Investor's Business Daily)
09:26AM	Novo Nordisks Wegovy Weight Loss Shot Approved At Higher Dose in U.K. (The Wall Street Journal)
08:27AM	Micro shares surge on share buying by board member, and more stocks on the move (MarketWatch)
07:37AM	Novo Nordisk Stock Rises After U.K. Approves Higher Wegovy Dose for Weight Loss (Barrons.com)
06:58AM	Shares in Novo Nordisk spike sharply after U.K. regulator approves higher Wegovy dosage (MarketWatch)
06:48AM	UK Approves Higher Wegovy Dose for Obesity; Novo Nordisk Shares Rise 3% (GuruFocus.com)
Jan-15-26 04:40PM	Amgens Weight-Loss Drug Shows Promise With Less Frequent Dosing (Barrons.com)
03:10PM	Trump unveils his 'Great Healthcare Plan.' Analysts don't expect much of an impact. (MarketWatch)
02:59PM	Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit (Benzinga)
02:25PM	Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers (Benzinga)
12:30PM	Health Care Roundup: Market Talk (The Wall Street Journal)
11:51AM	Half of GLP-1 users ditch their injections - and some are turning to other weight-loss methods instead (MarketWatch)
11:50AM	Novo Nordisk Foundation Commits Up to $860 Million to European Innovation Push (GuruFocus.com)
11:07AM	Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments (Benzinga)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience